KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biolife Solutions (BLFS) EBT (2016 - 2025)

Biolife Solutions (BLFS) has disclosed EBT for 16 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 616.84% to $3.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.1 million, a 36.93% decrease, with the full-year FY2025 number at -$12.1 million, down 36.93% from a year prior.
  • EBT was $3.4 million for Q4 2025 at Biolife Solutions, up from $703000.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $89.7 million in Q4 2022 to a low of -$76.6 million in Q2 2022.
  • A 5-year average of -$2.5 million and a median of -$4.8 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: crashed 1538.52% in 2022, then soared 616.84% in 2025.
  • Biolife Solutions' EBT stood at -$18.3 million in 2021, then soared by 589.36% to $89.7 million in 2022, then plummeted by 54.71% to $40.6 million in 2023, then crashed by 98.85% to $469000.0 in 2024, then skyrocketed by 616.84% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for BLFS's EBT are $3.4 million (Q4 2025), $703000.0 (Q3 2025), and -$15.7 million (Q2 2025).